Doug,
(Very cool first name, by the way). I was diagnosed CML - accelerated phase July 2007. I started on hydrea for a few days to reduce the overall white cell counts. I was accepted into a clinical trial for a new drug that was later approved as Tasigna. Tasigna is very similar to Gleevec in how it works - it was developed by the same company as Gleevec with the intent to reduce the side effect profile, and improve the durability of response to variations of the Ph+ mutation that are resistant to Gleevec. I was improved to something like chronic phase within a few of weeks. Back to normal, really - just a little more easily tired out than a year earlier. The improvements from that point have been measurable by blood and marrow analysis. Improvements in energy levels have been slower, but I have to admit that I haven't been trying to exercise or eat as sensibly as I should. I gained back the 35 lbs I had lost before diagnosis in about 6 months. The spleen was normal sized at my one month follow up exam. The anemia was severe at first, bad enough that I had to be transfused twice. Since the first month, the anemia has slowly improved to where I am stable at approximately the low end of normal.
I think the entire chronic, accelerated, blastic phase thing is becoming less important as a measure of patients' progress now that there are drugs that actually work reliably for most patients. The progression of phases was a more useful way to classify the conditions of patients who were not really expected to be "permanently" in remission. About 10 years ago when Gleevec came out, the average patient's prognosis improved so that it is now more useful to describe the patients' condition in terms of their degree of success. The old chronic, accelerated, and blastic stages are giving way to hematologic, cytogenic or molecular as descriptive of the degree of the patients' improved response to treatment. Phase descriptions are still used, but it seems like they are more often used during diagnosis to help classify a patient before treatment. After treatment begins, the degree of response becomes the more common measure.
This leads to something else that you should be clear on as a newly diagnosed CML patient. A lot of information about CML and various treatments available to us who are not medical professionals is out of date. Be careful about reading too much into anything that talks in terms of five-year survival statistics, etc. Many of these were written before Gleevec, when surviving 5 years was a very big success. Gleevec, Sprycel and Tasigna are such good treatments, that the long term survival statistics are impossible to calculate meaningfully. Gleevec has only been used for a little more than 10 years. It is impossible to predict what the 25 year survival rate stats will be with only 10 years of data accumulated.
It surprised me that the best (most up to date) information I could get on CML and various treatments was nearly always right here on this board. I'm not advocating collective experience as a substitute for doctor consultation, or peer-reviewed research. However, people on this board have pointed out information sources that have proved valuable (as well as comforting) to me as I learn more about my condition.
Doug